Du et al. (1) combine multiomics analyses, genetic perturbation, in vivo experiments, and IL-1β neutralization to implicate ALDH9A1 in immunotherapy resistance in non–small-cell lung cancer. Their findings support functional associations involving ALDH9A1, acetyl-CoA, and IL-1β-related phenotypes, but the proposed role of carnitine as the necessary intermediate remains insufficiently established.
We could not identify compound-resolved measurements of free carnitine, γ-butyrobetaine, 4-trimethylaminobutyraldehyde, or clearly annotated total carnitine and acylcarnitine pools in the main text or SI Appendix. Although Fig. 1L of ref. 1 refers to ‘multiple carnitine-related metabolites,’ their chemical identities, annotation confidence, and quantitative values are not clearly reported. Without compound-level validation and targeted quantification, these signals cannot be taken as direct evidence of increased free-carnitine abundance or increased flux through carnitine biosynthesis.
ALDH9A1 catalyzes the oxidation of 4-trimethylaminobutyraldehyde to γ-butyrobetaine, a canonical step in carnitine biosynthesis (2–4). This position provides a rationale for studying ALDH9A1, but it does not by itself establish ALDH9A1 as a committed or rate-controlling step in NSCLC cells. Increased ALDH9A1 expression alone does not demonstrate increased intracellular free-carnitine abundance or pathway flux, as these depend on substrate availability, downstream enzyme activity, transport, and cellular carnitine handling.
The reported acetyl-CoA measurements support associations with ALDH9A1 perturbation and IL-1β phenotypes, but do not establish that carnitine is a necessary intermediate. Carnitine can reversibly buffer acetyl groups through acetylcarnitine formation. Thus, altered acetyl-CoA levels do not on their own demonstrate carnitine dependence. The data also do not exclude alternative effects of ALDH9A1 perturbation on aldehyde metabolism, mitochondrial acetyl-group handling, or related processes.
Targeted measurements of carnitine, γ-butyrobetaine, and acylcarnitine species, together with carnitine add-back and stable-isotope tracing from labeled trimethyllysine and/or γ-butyrobetaine, would help determine whether altered carnitine biosynthetic flux contributes to the acetyl-CoA and IL-1β phenotypes. Rescue of ALDH9A1-loss phenotypes by carnitine, particularly when accompanied by restoration of acetylcarnitine flux, would provide stronger evidence for mediation.
The current results therefore support a biologically plausible model linking ALDH9A1 to acetyl-CoA and IL-1β-related phenotypes, but do not yet establish carnitine as the causal mediator. We suggest presenting the ALDH9A1–carnitine–acetyl-CoA–IL-1β relationship as a hypothesis-generating model rather than as a fully validated linear causal axis. Fig. 1 illustrates the evidence gaps in this proposed model.
Fig. 1.

Reported associations and unresolved causal links in the proposed ALDH9A1–carnitine–acetyl-CoA–IL-1β model. (A) Relationships reported by Du et al. are shown as associations rather than as a complete causal pathway. (B) The established, reversible CRAT-catalyzed transfer of an acetyl group between acetyl-CoA and carnitine is shown as proposed metabolic context; its engagement in the NSCLC model has not been directly established. (C) Key unresolved questions include whether carnitine-dependent flux is required for the ALDH9A1–acetyl-CoA relationship and whether changes in carnitine or acetylcarnitine causally affect the inflammatory phenotype. Solid arrows indicate reported associations; dashed arrows in the proposed-context color indicate established biochemical relationships used as mechanistic context; dashed arrows in the unresolved color indicate causal or model-specific links that remain untested.
Acknowledgments
Data, Materials, and Software Availability
There are no data underlying this work.
Author contributions
T.Y. and W.Y. designed research; and wrote the paper.
Competing interests
The authors declare no competing interest.
References
- 1.Du H., et al. , Single-cell multiomics identifies an ALDH9A1–carnitine signaling axis driving resistance of NSCLC to immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 123, e2535328123 (2026). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Wyatt J. W., et al. , Inhibition, crystal structures, and in-solution oligomeric structure of aldehyde dehydrogenase 9A1. Arch. Biochem. Biophys. 691, 108477 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Vaz F. M., Wanders R. J., Carnitine biosynthesis in mammals. Biochem. J. 361, 417–429 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Li X., et al. , Biallelic variants in BBOX1 cause L-carnitine deficiency and elevated γ-butyrobetaine. NPJ Genom. Med. 10, 64 (2025). [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
There are no data underlying this work.
